Finance

Beta
Lists
PHVS:NASDAQ
Pharvaris NV
$33.50
+0.93%
(+0.31) 1D
Jun 24, 12:03:56 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PHVS...
Open
$33.24
High
$34.05
Low
$33.04
Mkt. cap
2.34B
Avg. vol.
342.28K
Volume
109.29K
52-wk high
$34.41
52-wk low
$16.72
EPS
-$3.13
Beta
-2.34
Shares outstanding
69.86M
No. of employees
134
Open
$33.24
High
$34.05
Low
$33.04
Mkt. cap
2.34B
Avg. vol.
342.28K
Volume
109.29K
52-wk high
$34.41
52-wk low
$16.72
EPS
-$3.13
Beta
-2.34
Shares outstanding
69.86M
No. of employees
134
News stories
From sources across the web
About Pharvaris NV
CEO-
Employees134
Founded2015
Headquarters-
SectorPharmaceutical industry
Websitepharvaris.com
Analyst Ratings
Based on 10 analysts giving stock ratings to PHVS in the past 3 months
Strong Buy
Buy
9
Hold
1
Sell
0
12 month forecast
Based on 10 Wall Street analysts offering 12 month price targets for PHVS in the last 3 months.
Highest
Current $33.50
$74.00 (+120.90%)
Average
$49.10 (+46.57%)
Lowest
$33.00 (-1.49%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$60.00
+79.1%
06/16/2026
Maxwell Skor
Morgan Stanley
Buy
Maintained
$41.00
+22.4%
06/15/2026
Debanjana Chatterjee
JonesTrading
Buy
Maintained
$52.00
+55.2%
06/11/2026
Tazeen Ahmad
Bank of America Securities
Hold
Maintained
$33.00
-1.5%
05/14/2026
Laura Chico
Wedbush
Buy
Maintained
$42.00
+25.4%
05/13/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
$50.00
+49.3%
05/13/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Reiterated
$46.00
+37.3%
05/12/2026
Nevin Varghese
RBC Capital
Buy
Maintained
$51.00
+52.2%
05/12/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$74.00
+120.9%
05/13/2026
Andy Chen
Wolfe Research
Buy
Initiated
$42.00
+25.4%
04/08/2026
Unknown Analyst
RBC Capital
Buy
Initiated
$52.00
+55.2%
03/09/2026
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
29.61M
29.81M
34.14M
30.16M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.77M
9.85M
13.46M
14.11M
Operating expense
40.37M
39.66M
47.60M
44.27M
Total operating expenses
40.37M
39.66M
47.60M
44.27M
Operating income
-40.37M
-39.66M
-47.60M
-44.27M
Other non operating income
-38.13K
-
-
-86.40K
EBT including unusual items
-45.28M
-37.32M
-45.08M
-38.93M
EBT excluding unusual items
-45.28M
-37.32M
-45.08M
-38.93M
Income tax expense
202.78K
-181.47K
1.66M
273.11K
Effective tax rate
-0.45%
0.49%
-3.69%
-0.70%
Other operating expenses
-
-
-
-
Net income
-45.48M
-37.14M
-46.74M
-39.20M
Net profit margin
-
-
-
-
Earnings per share
-0.83
-0.60
-0.71
-0.60
Interest and investment income
1.00M
2.15M
2.19M
1.67M
Interest expense
-
-50.03K
-58.74K
-
Net interest expenses
1.00M
2.10M
2.13M
1.67M
Depreciation and amortization charges
-
-
-
-
EBITDA
-40.33M
-39.62M
-47.55M
-44.22M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer